211244-80-3

Usage

Uses

Used in Pharmaceutical Industry:
(E)-ethyl 3-(4-amino-2-(methylthio)pyrimidin-5-yl)acrylate is used as a key intermediate in the synthesis of drugs targeting specific biological processes. Its pyrimidine-based structure allows for the development of compounds that can interact with enzymes, receptors, or other biological targets, potentially leading to the creation of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (E)-ethyl 3-(4-amino-2-(methylthio)pyrimidin-5-yl)acrylate serves as a versatile building block for the creation of more complex organic molecules. Its functional groups can be further modified or used as starting points for the synthesis of a wide range of compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Chemical Research:
(E)-ethyl 3-(4-amino-2-(methylthio)pyrimidin-5-yl)acrylate is also of interest to researchers in chemical research. Its unique structure and potential reactivity make it a valuable subject for studying reaction mechanisms, exploring new synthetic methods, and understanding the properties of pyrimidine derivatives. This research can contribute to the advancement of chemical knowledge and the development of new applications for (E)-ethyl 3-(4-aMino-2-(Methylthio)pyriMidin-5-yl)acrylate.

Upstream product

• 770-31-0 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 588-36-3 (4-amino-2-(methylthio)pyrimidin-5-yl)methanol 
• 776-53-4 ethyl 4-amino-2-methylmercaptopyrimidine-5-carboxylate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

FGFR INHIBITOR AND APPLICATION THEREOF

An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. AA%%%Formula (I).

Pyrido[2,3-d]pyrimidin-7(8H)-one derivatives and Composition for skin whitening and Pharmaceutical composition for use in preventing or treating disorders of Melanin Hyperpigmentation containing the same as an active ingredient

The present invention relates to a pyrido[2,3-d]pyrimidin-7(8H)-one derivative, and to a composition for skin whitening comprising the same as an active ingredient. Since the derivative exhibits an effect of inhibiting the production of melanin even when

Pyridopyrimidinone derivatives as potent and selective c-jun N-terminal kinase (JNK) inhibitors

A novel series of 2-aminopyridopyrimidinone based JNK (c-jun N-terminal kinase) inhibitors were discovered and developed. Structure-activity relationships (SARs) were systematically developed utilizing biochemical and cell based assays and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies. Through the optimization of lead compound 1, several potent and selective JNK inhibitors with high oral bioavailability were developed. Inhibitor 13 was a potent JNK3 inhibitor (IC50 = 15 nM), had high selectivity against p38 (IC50 > 10 μM), had high potency in functional cell based assays, and had high stability in human liver microsome (t1/2 = 76 min), a clean CYP-450 inhibition profile, and excellent oral bioavailability (%F = 87). Moreover, cocrystal structures of compounds 13 and 22 in JNK3 were solved at 2.0 ?. These structures elucidated the binding mode (Type-I binding) and can pave the way for further inhibitor design of this pyridopyrimidinone scaffold for JNK inhibition.

Pyridopyrimidinone derivatives for treatment of neurodegenerative disease

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di

Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors

Disclosed are compounds of the formula (I) wherein: R2, R7, RI3, R14 and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted —(CH2)nR12; R5 is halogen, cyano, nitro, —R9, —NR9R10, or —OR9; R6 is halogen, cyano, nitro, —R9, —NR9R10, —OR9, —Co2R9, —COR9, —CONR9R10, —NR9COR10, (un)substiuted lower alkenyl, or (un)substituted lower alkynyl; R8 is —CO2R13, —COR13, —CONR13R14, —CSNR13R14, —C(NR13)NR14R15, —SO3R13, —SO2R13, —SO2NR13R14, —PO3R13R14, —POR13R14, —PO(NR13R14)2; R9 and R10 are independently hydrogen or (un)substituted lower alkyl; R11 is a heteroaryl or a heterocyclic group; R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.

Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-dia